Immunogenicity in CGT: beyond Anti-Drug Antibody (ADA) testing [WEBINAR]

As cell and gene therapies evolve, robust approaches for immunogenicity assessment are becoming increasingly important across preclinical and clinical research. In this webinar, our experts discuss practical workflows that extend beyond conventional Anti-Drug Antibody (ADA) testing, including key assays, risk factors, biomarker-based approaches, and assay validation strategies. Learn how these methods can support immunogenicity characterization and risk assessment throughout the development process. Sign in to Miltenyi University to view the slides from the video and explore more learning opportunities. miltenyibiotec.com/university